<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903081</url>
  </required_header>
  <id_info>
    <org_study_id>HEC110114-P-01</org_study_id>
    <nct_id>NCT03903081</nct_id>
  </id_info>
  <brief_title>The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects</brief_title>
  <acronym>HEC110114</acronym>
  <official_title>A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single &amp; Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single &amp; Multiple
      Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in
      Healthy Adult Subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Actual">October 29, 2019</completion_date>
  <primary_completion_date type="Actual">October 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From Days 1-12</time_frame>
    <description>Percentage of Participants with Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>At pre-defined intervals from Days 1-12</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>At pre-defined intervals from Days 1-12</time_frame>
    <description>Time to Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>At pre-defined intervals from Days 1-12</time_frame>
    <description>Area Under the Plasma Concentration vs Time Curve to Last Measurable Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>At pre-defined intervals from Days 1-12</time_frame>
    <description>Area Under the Plasma Concentration vs Time Curve Extrapolated to Infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>At pre-defined intervals from Days 1-12</time_frame>
    <description>Apparent Half-Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>At pre-defined intervals from Days 1-12</time_frame>
    <description>Clearance (CL/F) of HEC110114</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>At pre-defined intervals from Days 1-11 for MAD</time_frame>
    <description>Trough Plasma Concentration of HEC110114</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>100 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It includes two groups, one group is pilot study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=2) . Another group is formal study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=8) or matching placebo (N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 300 mg HEC110114 tablet (N=8) or matching placebo (N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 600 mg HEC110114 tablet (N=8) or matching placebo (N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 800 mg HEC110114 tablet (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 1000 mg HEC110114 tablet (N=8) or matching placebo (N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 1200 mg HEC110114 tablet (N=8) or matching placebo (N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1600 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 1600 mg HEC110114 tablet (N=8) or matching placebo (N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving 600 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving 800 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving 1000 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC110114 tablet</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>100 mg single dose</arm_group_label>
    <arm_group_label>1000 mg multiple doses</arm_group_label>
    <arm_group_label>1000 mg single dose</arm_group_label>
    <arm_group_label>1200 mg single dose</arm_group_label>
    <arm_group_label>1600 mg single dose</arm_group_label>
    <arm_group_label>300 mg single dose</arm_group_label>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_label>600 mg single dose</arm_group_label>
    <arm_group_label>800 mg multiple doses</arm_group_label>
    <arm_group_label>800 mg single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo will be administered orally at a dose and frequency matched to HEC110114</description>
    <arm_group_label>100 mg single dose</arm_group_label>
    <arm_group_label>1000 mg multiple doses</arm_group_label>
    <arm_group_label>1000 mg single dose</arm_group_label>
    <arm_group_label>1200 mg single dose</arm_group_label>
    <arm_group_label>1600 mg single dose</arm_group_label>
    <arm_group_label>300 mg single dose</arm_group_label>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_label>600 mg single dose</arm_group_label>
    <arm_group_label>800 mg multiple doses</arm_group_label>
    <arm_group_label>800 mg single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign the informed consent form before the trial and fully understand the contents of
             the trial, the process and possible adverse reactions

          -  Be able to complete the study according to the trail protocol

          -  Subjects (including partners) have no pregnancy plan within six months after the last
             dose of study drug and voluntarily take effective contraceptive measures

          -  Male subjects and must be 18 to 45 years of age inclusive

          -  Body weight ≥ 50 kg and body mass index（BMI）between 18 and 28 kg/m2, inclusive

          -  Physical examination and vital signs without clinically significant abnormalities.

        Exclusion Criteria:

          -  Use of &gt;5 cigarettes per day during the past 3 months

          -  Allergies constitution ( multiple drug and food allergies)

          -  History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25
             mL of spirits or 100 mL of wine)

          -  Donation or loss of blood over 450 mL within 3 months prior to screening

          -  12-lead ECG with clinically significant

          -  Positive for Viral hepatitis (including hepatitis B and C), HIV and syphilis

          -  Subjects deemed unsuitable by the investigator for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

